Pd37-01 the Clinical Efficacy of Psma Pet/Mri in Biochemically Recurrent Prostate Cancer Compared With Standard of Care Imaging Modalities - Results of a Multi-Centre, Prospective Clinical Trial

Joshi, Andre; Rhee, Handoo; Pryor, David; Lehman, Margot; McKenzie, Ian; Munns, Janelle; Malone, Greg; Chung, Eunna; Heathcote, Peter; Preston, John; Lawson, Malcolm; Wood, Simon; Gustafson, Sonja; Miles, Kenneth; Vela, Ian

doi:10.1016/j.juro.2018.02.1736

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 In addition to PET/CT, current studies suggest that the PSMA PET/MRI offers even further advantages by identifying lymph-node metastases that would have been missed on CT. 14 This method of PSMA PET/MRI has been seen to be particularly useful when PSA levels are low, showing a high detection rate for locally recurrent disease. 15 In addition, PSMA has further theranostic applications in local salvage therapy, such as in the use of lutetium-177-labelled PSMA ( 177 Lu-PSMA), which directly treats prostate cancers with the added benefit of a reduction in side effects. 16 Beyond local therapy, treatment with 177 Lu-PSMA has also been seen to have high response rates in patients with PSMA-avid metastatic prostate cancer that is castration resistant.…”

Section: Imaging and Diagnosticsmentioning

confidence: 99%

Urological technology: where will we be in 20 years’ time?

Bernstein

2018

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Since prehistoric times, our understanding of urology has rapidly expanded. Whilst primitive urologists began by using urine as a therapeutic substance, modern urologists may find themselves removing a kidney remotely by driving a robotic arm, with seven degrees of movement, while using image overlay-augmented reality. This review provides an insight into the potential status of urological technology in 20 years' time, assessed through an analysis of developments in imaging, diagnostics, robotics and further technologies. A particular emphasis is given to the promising fields of minimally invasive techniques, nanotechnology and tissue engineering, which likely hold the key to a new era for urology.

show abstract

Section: Imaging and Diagnosticsmentioning

confidence: 99%

Urological technology: where will we be in 20 years’ time?

Bernstein

2018

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

Pd37-01 the Clinical Efficacy of Psma Pet/Mri in Biochemically Recurrent Prostate Cancer Compared With Standard of Care Imaging Modalities - Results of a Multi-Centre, Prospective Clinical Trial

Cited by 1 publication

References 0 publications

Urological technology: where will we be in 20 years’ time?

Urological technology: where will we be in 20 years’ time?

Contact Info

Product

Resources

About